| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Neuromuscular Diseases Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892;
Arrowsmith Technologies, Seattle, WA 98103;
King’s College London, Division of Gene and Cell Based Therapy, King’s College School of Medicine, London, United Kingdom;
Department of Medicine, University of Washington, Seattle, WA 98195;
¶
Department of Chemical Pathology, University of the Witwaterstrand and National Health Laboratory Services, Johannesburg, South Africa; and
||
Department of Women and Child Health, Karolinska Institutet, Stockholm, Sweden
Autoantibodies to the 65-kDa isoform of glutamate decarboxylase GAD65 (GAD65Ab) are strong candidates for a pathological role in Stiff-Person syndrome (SPS). We have analyzed the binding specificity of the GAD65Ab in serum and cerebrospinal fluid (CSF) of 12 patients with SPS by competitive displacement studies with GAD65-specific rFab-derived from a number of human and mouse mAbs specific for different determinants on the Ag. We demonstrate considerable differences in the epitope specificity when comparing paired serum and CSF samples, suggesting local stimulation of B cells in the CSF compartment of these patients. Moreover, these autoantibodies strongly inhibit the enzymatic activity of GAD65, thus blocking the formation of the neurotransmitter 
-aminobutyric acid. The capacity of the sera to inhibit the enzymatic activity of GAD65 correlated with their binding to a conformational C-terminal Ab epitope. Investigation of the inhibitory mechanism revealed that the inhibition could not be overcome by high concentrations of glutamate or the cofactor pyridoxal phosphate, suggesting a noncompetitive inhibitory mechanism. Finally, we identified a linear epitope on amino acids residues 4–22 of GAD65 that was recognized solely by autoantibodies from patients with SPS but not by serum from type 1 diabetes patients. A mAb (N-GAD65 mAb) recognizing this N-terminal epitope was successfully humanized to enhance its potential therapeutic value by reducing its overall immunogenicity.
This article has been cited by other articles:
|
|
 |
|
  G. Fenalti, C. S. Hampe, Y. Arafat, R. H.P. Law, J. P. Banga, I. R. Mackay, J. C. Whisstock, A. M. Buckle, and M. J. Rowley COOH-Terminal Clustering of Autoantibody and T-Cell Determinants on the Structure of GAD65 Provide Insights Into the Molecular Basis of Autoreactivity Diabetes, May 1, 2008; 57(5): 1293 - 1301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Oak, L. K. Gilliam, M. Landin-Olsson, C. Torn, I. Kockum, C. R. Pennington, M. J. Rowley, M. R. Christie, J. P. Banga, and C. S. Hampe The lack of anti-idiotypic antibodies, not the presence of the corresponding autoantibodies to glutamate decarboxylase, defines type 1 diabetes PNAS, April 8, 2008; 105(14): 5471 - 5476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Candeloro, C. B. Voltattorni, R. Perniola, M. Bertoldi, C. Betterle, M. Mannelli, R. Giordano, A. De Bellis, C. Tiberti, S. Laureti, et al. Mapping of Human Autoantibody Epitopes on Aromatic L-Amino Acid Decarboxylase J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1096 - 1105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Hampe, R. Nalini, M. R. Maldonado, T. R. Hall, G. Garza, D. Iyer, and A. Balasubramanyam Association of Amino-Terminal-Specific Antiglutamate Decarboxylase (GAD65) Autoantibodies with {beta}-Cell Functional Reserve and a Milder Clinical Phenotype in Patients with GAD65 Antibodies and Ketosis-Prone Diabetes Mellitus J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 462 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Raju, G. Rakocevic, Z. Chen, G. Hoehn, C. Semino-Mora, W. Shi, R. Olsen, and M. C. Dalakas Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome Brain, December 1, 2006; 129(12): 3270 - 3276. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
